Revolution Medicines (RVMD) Retained Earnings (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Retained Earnings of -$622000.0 for Q1 2026, up 99.97% year-over-year from -$311048.4 in Q1 2025, and down 119.22% quarter-over-quarter from $3.2 million in Q4 2025.
Revolution Medicines (RVMD) Retained Earnings (2019 - 2026) Analysis & Trends
Revolution Medicines' Retained Earnings history runs 8 years deep, the most recent figure standing at -$622000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 99.97% year-over-year to -$622000.0; the TTM figure through Mar 2026 stood at -$622000.0 (up 99.97% YoY), while the FY2025 annual figure was $3.2 million, up 145.04% from the prior year.
- Retained Earnings for Q1 2026 stood at -$622000.0, down from $3.2 million in the prior quarter.
- The five-year high for Retained Earnings was $3.2 million in Q4 2025, with the low at -$2.5 billion in Q3 2025.
- The 5-year median for Retained Earnings is -$2.4 million (2022), against an average of -$704.2 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings plunged 177079.33% in 2024, then jumped 145.04% in 2025.
- Revolution Medicines' Retained Earnings stood at -$701.3 million in 2022, then soared by 100.08% to $544000.0 in 2023, then soared by 142.83% to $1.3 million in 2024, then soared by 145.04% to $3.2 million in 2025, then slumped by 119.22% to -$622000.0 in 2026.
- Business Quant data shows RVMD's Retained Earnings at -$622000.0 in Q1 2026, $3.2 million in Q4 2025, and -$2.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.00 Bn |
| Mar 31, 2026 | -622,000.00 |
| Dec 31, 2025 | 3.24 Mn |
| Sep 30, 2025 | -2.50 Bn |
| Jun 30, 2025 | -2.20 Bn |
| Mar 31, 2025 | -2.00 Bn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | -1.54 Bn |
| Jun 30, 2024 | -1.39 Bn |
| Mar 31, 2024 | -1.20 Mn |
| Dec 31, 2023 | 544,000.00 |
| Sep 30, 2023 | -871,000.00 |
| Jun 30, 2023 | -867.70 Mn |
| Mar 31, 2023 | -769.40 Mn |
| Dec 31, 2022 | -701.34 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | -1.77 Mn |
| Mar 31, 2022 | -1.28 Mn |
| Dec 31, 2021 | -452.64 Mn |
| Sep 30, 2021 | -399.96 Mn |